YAVNE, Israel--(BUSINESS WIRE)--Neviah Genomics announced today that it had discovered and experimentally validated a set of biomarkers for the early detection of chronic drug-induced liver toxicity. Based on these results, the company is moving toward the further development of its PropheTox™ Bioassay, targeting 2016 for its commercial introduction. Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen, and is operating from MS Ventures’ Israel Bioincubator in Yavne, Israel.
Help employers find you! Check out all the jobs and post your resume.
